Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30963128 | 1.00 | LMNA (0.43) | LMNAMEN1ALDH1A1HPGDKMT2A | |
| Ethoxycarbonyl Group SCHEMBL29268439 | 0.83 | ALDH1A1 (0.36) | LMNAMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL4065234 | 0.73 | CHEK1 (0.42) | MEN1ALDH1A1HPGDKMT2APDGFRB | |
| SCHEMBL27141229 | 0.73 | MEN1 (0.34) | LMNAMEN1KMT2A | |
| SCHEMBL13454732 | 0.72 | CCR1 (0.38) | ALDH1A1HPGD | |
| SCHEMBL28125752 | 0.72 | ALDH1A1 (0.56) | LMNAMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL348168 | 0.72 | KDM4E (0.46) | LMNAMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL4069291 | 0.72 | MEN1 (0.36) | LMNAMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL645949 | 0.71 | NQO2 (0.47) | LMNAMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL23937934 | 0.71 | ALDH1A1 (0.36) | LMNAMEN1ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4582425-A1 | PRODRUG OF JAK KINASE INHIBITOR | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd (CN) | 2025-07-09 | — | — | EP | disclosed |
| CN-118324772-A | Synthesis method and intermediate of furan [3,2-b ] pyridine derivative | 北京颖诺凯胜科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2024041586-A1 | PRODRUG OF JAK KINASE INHIBITOR | 启元生物(杭州)有限公司 | 2024-02-29 | — | — | WO | disclosed |
| US-10738060-B2 | JAK1 selective inhibitors and uses thereof | TLL Pharmaceutical, LLC (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190256523-A1 | NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF | HANGZHOU HIGHLIGHTII PHARMACEUTICAL CO., LTD (CN) | 2019-08-22 | — | — | US | disclosed |
| WO-2018067422-A1 | NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF | LIANG CONGXIN (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738060-B2 | JAK1 selective inhibitors and uses thereof | JAK1, JAK3, JAK2 | LMNA 4818/4885MEN1 1549/4885ALDH1A1 1860/4885 |
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | LMNA 2664/4885MEN1 4564/4885ALDH1A1 1710/4885 |
| US-20190256523-A1 | NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF | JAK1, JAK3, JAK2 | LMNA 4833/4885MEN1 2184/4885ALDH1A1 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.